Evolution of the Average Target: Beta Bionics, Inc.

Evolution of the Average Target - Beta Bionics, Inc.

Evolution of the Target Price: Beta Bionics, Inc.

Evolution of the Target Price - Beta Bionics, Inc.

Changes in Analyst Recommendations: Beta Bionics, Inc.

962eb3e66898cdc391b0b72f34c4903.vkOregx7MJifjdQf1g17Y7MrTxitX9e7eZEirD76zxY.0haYC3YrYf3Y2Z8yrCAkPPxGKVCAFLreP_lJnkyxik_rKpgjWStgyP3dmQ~9e9a4fa61bc3b069ec88c0bce1a91da6
08:16am Barclays Initiates Beta Bionics at Overweight With $30 Price Target MT
09-24 Truist Raises Price Target on Beta Bionics to $28 From $23, Keeps Buy Rating MT
09-23 Wells Fargo Initiates Beta Bionics at Overweight With $28 Price Target MT
09-16 Beta Bionics Shares Rise After BofA Price-Target Boost, $150 Million Offering Priced MT
09-16 BofA Adjusts Price Target on Beta Bionics to $20 From $18 MT
09-14 Truist Lifts Price Target on Beta Bionics to $23 From $22, Keeps Buy Rating MT
08-12 BofA Securities Adjusts Price Target on Beta Bionics to $18 From $15.50 MT
08-11 BofA Securities Adjusts Beta Bionics Price Target to $18 From $15.50 MT
07-28 UBS Adjusts Price Target on Beta Bionics to $22 From $24, Maintains Buy Rating MT
07-13 Truist Raises Price Target on Beta Bionics to $22 From $18, Keeps Buy Rating MT
05-18 BofA Adjusts Price Target on Beta Bionics to $11 From $23 MT
04-15 Truist Cuts Price Target on Beta Bionics to $18 From $25, Keeps Buy Rating MT
02-09 UBS Initiates Coverage on Beta Bionics With Buy Rating, $24 Price Target MT
02-02 Truist Trims Price Target on Beta Bionics to $25 From $37, Keeps Buy Rating MT
01-27 TD Cowen Initiates Beta Bionics at Hold WIth Price Target $17 MT
01-09 Top Midday Decliners MT
01-09 Beta Bionics Shares Fall After BofA Securities Downgrade MT
01-09 BofA Securities Downgrades Beta Bionics to Neutral From Buy, Adjusts Price Target to $28 From $33 MT
12-18 Truist Securities Adjusts Price Target on Beta Bionics to $37 From $32, Maintains Buy Rating MT
25-10-29 Truist Raises Price Target on Beta Bionics to $32 From $28, Keeps Buy Rating MT
25-10-01 Goldman Sachs Upgrades Beta Bionics to Buy From Neutral, Adjusts Price Target to $26 From $18 MT
25-09-22 Truist Raises Price Target on Beta Bionics to $28 From $21, Keeps Buy Rating MT
25-07-30 Truist Raises Price Target on Beta Bionics to $21 From $18, Keeps Buy Rating MT
25-06-16 Truist Securities Initiates Beta Bionics at Buy With $26 Price Target MT
25-05-30 Wolfe Research Initiates Coverage on Beta Bionics With Outperform Rating, $20 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+27.75%
+1.31%
+10.87%
+17.96%
+41.97%
+17.9%
+4.23%
+19.57%
+4.87%
-18.17%
Average +12.83%
Weighted average by Cap. +10.37%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
18.63USD
Average target price
23.80USD
Spread / Average Target
+27.75%
High Price Target
30.40USD
Spread / Highest target
+63.18%
Low Price Target
16.00USD
Spread / Lowest Target
-14.12%

Analyst Consensus Detail

Analyst consensus - Beta Bionics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Beta Bionics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Beta Bionics, Inc.
  1. Stock Market
  2. Stocks
  3. BBNX Stock
  4. Consensus Beta Bionics, Inc.